Results 121 to 130 of about 83,236 (262)
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam +3 more
wiley +1 more source
Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang +4 more
wiley +1 more source
Population pharmacokinetics for the CTLA-4 modulator gotistobart in patients with advanced solid tumors. [PDF]
Li T +12 more
europepmc +1 more source
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka +3 more
wiley +1 more source
Lung cancer brain metastasis is shaped by dynamic crosstalk among tumor cells, the blood–brain barrier, glial and immune cells, neurons, and metabolic niches. This review integrates these mechanisms with therapeutic resistance, translational models, CNS delivery, and multidisciplinary treatment strategies.
Jun Yang +6 more
wiley +1 more source
The effect of a PD-1/CTLA-4 tandem scFv on T cell cytokine response under immunosuppressive conditions. [PDF]
Maleki F +4 more
europepmc +1 more source
SLAMF6 recruits SHP‐2 to activate STAT1, upregulates CXCL10 and PD‐L1, promotes CD8+T cell infiltration, and enhances the efficacy of anti‐PD‐L1 therapy. ABSTRACT As a T‐cell receptor co‐stimulatory protein, signaling lymphocyte activation molecule family 6 (SLAMF6) is a member of the immune cell activating receptor family and is expressed on T cells ...
Yu Wu +8 more
wiley +1 more source

